Introduction
Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder characterized by a shortened life expectancy and a progressive clinical course. 1 Heterogeneity of disease presentations with frequent development of large splenomegaly, severe anemia and acute leukemia is the hallmark of the disease. The distinction of different classes of disease presentation useful for therapeutic decisions is based on studies that have recognized prognostic factors, including age, Hb level, white-blood cell count, plt count, and these parameters have been incorporated into algorithms for risk assessment. 2, 3, 4 The current available treatment for PMF, including transfusions, androgens, thalidomide and myelosuppressive agents such as hydroxyurea, does not seem to modify the natural course of the disease. The recent identification of JAK2 mutations 5 in approximately 60% of patients with PMF has opened new areas of investigation, but targeted inhibitors are currently not yet available for clinical use.
Allogeneic hemopoietic SCT (HSCT), on the contrary, has been shown to cure 50-70% of PMF patients, but unfortunately with a variable degree of TRM. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Usually, PMF patients are referred for allogeneic HSCT when the Dupriez's risk score, 2 based on Hb and WBC count, is intermediate or high, whereas patients with a low-risk disease are usually monitored without treatment until progression. Other risk-assessment scores for transplant eligibility have been introduced. They take into account the presence of constitutional symptoms and blasts (Cervantes score) 3 or plt count besides Hb and WBCs (Mayo score). 4 However, these scoring systems are constructed using parameters measured at diagnosis and are based on outcome of conventional treatment; thus, they are not necessarily applicable to the transplant setting.
The aim of the present study was to identify variables predicting transplant outcome in a cohort of 40 consecutive patients with PMF who were referred to the Transplant Unit of the Ospedale San Martino in Genova.
Patients and methods

Patients
We included in this study all 46 patients with PMF who were referred to the Transplant Unit of the Ospedale San Martino, Genova, and who were transplanted between 1994 and 2007. The diagnosis of PMF was established according to the Italian Consensus Conference criteria, 17 as per which the diagnosis holds if diffuse BM fibrosis is present. All PMF patients also fulfilled the recent WHO criteria for fibrotic myelofibrosis. 18 Most patients were referred to the Italian Registry of Myelofibrosis and were enrolled in this study by one of the authors (GB).
Variables collected from all patients included demographic data, physical examination, BM biopsy and complete blood count with differential serum lactate dehydrogenase level and the measurement of the number of circulating CD34 þ cells. 19 WBC count was corrected for the number of circulating erythroblasts. Circulating nucleated cells were classified as immature myeloid cells, erythroblasts and blasts. Blasts were defined as undifferentiated cells with an immature nucleolated nucleus and basophilic cytoplasm with or without azurophilic granules. The size of the spleen was assessed by ultrasonography by measuring the length of the longitudinal axis. Acute leukemia-like chemotherapy was recorded in patients receiving a combination of anthracyclines and Ara-C for progressive leukocytosis with blasts. Patients were also classified according to Dupriez's algorithm, the so called Dupriez score, 2 which confers a score of 0 for Hb concentration 4100 g/l and a WBC count between 4 Â 10 9 /l and 30 Â 10 9 /l (worst value in the past 3 months pre-transplant), a score of 1 for either Hb concentration o100 g/l or a WBC count of more than 30 Â 10 9 /l or less than 4 Â 10 9 /l, and a score of 2 was assigned if both the Hb and WBC values were in those aberrant ranges.
Patients were also classified according to the new IPSS (International Prognostic Scoring System) score of the International Working Group for Myelofibrosis 20 . Clinical data of patients are outlined in Table 1 . All patients gave a written informed consent before transplant.
Transplant procedures
All 46 patients received reduced-intensity conditioning (RIC) on the basis of the combination of thiotepa (5 mg/ kg Â 2 or 5 mg/kg Â 3) and CY (60 mg/kg Â 2) (THIO-CY). 21 A total of 21 patients received an additional dose of melphalan (30 mg/m 2 in the unrelated transplants and 60 mg/m 2 in the HLA-identical sibling transplants) (THIO-CY-MEL). GVHD prophylaxis consisted of conventional CYA and MTX. The stem cell source was BM in 34 patients and peripheral blood (PB) in 12 patients. All transplants were unmanipulated. Management of bacterial, viral and fungal infections was carried out according to the Institutional protocols. In 28 patients, splenectomy was performed 1-3 months before transplant, after prophylaxis against Pneumococcus, Haemophilus influenzae and Neisseria meningitidis. Acute and chronic GVHD was scored according to the published criteria. 22, 23 Statistical analysis and transplant risk score The primary end point was survival. Variables considered in the prediction analysis were age, Hb level, WBC counts, PB blast count, absolute number of circulating CD34 þ cells and spleen size. For the clinico-hematological variables, the worst value ever attained during the last 3 pretransplant months of disease duration was considered. Moreover, the prediction analysis also considered having or not having received an acute leukemia-like chemotherapy, percentage of blasts on BM biopsy, number of pre-transplant units of red cell transfused and donor characteristics. To establish a cutoff point between low and high levels, the median value was used for continuous variables. The cutoff value was selected for some variables based on the biological plausibility. A BM blast count of 5% was chosen as this is the cutoff for remission in patients with acute leukemia, and as a small percentage of marrow blasts can be observed in some patients, without necessarily implying transformation of the disease.
All variables were tested in univariate analysis on survival. Variables that predicted survival after transplant (Po0.1) were tested in a multivariate Cox analysis, and the one that independently predicted survival was used to construct the transplant risk score. TRM and relapserelated death (RRD) are expressed as cumulative incidence and are competing causes of death. The actuarial survival was calculated according to Kaplan and Meier.
Results
Transplant outcome
The overall actuarial 5-year survival is 45% ( Figure 1) ; the cumulative incidence of TRM is 24% and the cumulative incidence of RRD is 26%. 
Univariate and multivariate analysis
In univariate analysis, unfavorable factors for survival were (1) more than 20 red blood cell transfusions, (2) a spleen size 422 cm, (3) a CD34 count 4126 and (4) a donor other than an HLA-identical sibling, referred to as an alternative donor (Table 2) . Patient/donor age and gender, interval between diagnosis and transplant, splenectomy, pre-transplant Dupriez score, pre-transplant IPSS score, marrow and PB blast count, acute leukemia-like chemotherapy, stem cell source (BM or PB) and regimen intensity were not predictive ( Table 2 ). In multivariate analysis on survival, more than 20 transfusions (RR, 4.43, P ¼ 0.002), spleen size greater than 22 cm (RR, 2.71, P ¼ 0.02) and an alternative donor (RR, 3.2, P ¼ 0.007) remained independent predictors of survival (Table 2) .
Transfusion requirement
In total, 21 patients had 0-20 transfusions and 25 patients had more than 20 transfusions pre-transplant. Survival in the two groups was, respectively, 71 vs 32% (P ¼ 0.007). In the heavily transfused patients, a higher proportion had marrow blasts 45% (28 vs 44%), required AMLlike chemotherapy (14 vs 28%) and presented with a CD34 count 4126 Â 10 6 /l (38 vs 64%). TRM in the two groups was not significantly different (19 vs 28%; P ¼ 0.4), but RRD was higher in heavily transfused patients (9 vs 40%; P ¼ 0.01); 15 of 21 and 8 of 25 patients survived (P ¼ 0.007).
Spleen size. Patients with a spleen larger than 22 cm had a trend for longer disease duration (530 days vs 1512 days), more patients had BM blasts 45% (46 vs 27%), more had circulating CD34 þ cell counts above the median (33 vs 65%) or required AML-like chemotherapy (13 vs 25%). TRM was 9 vs 27% in patients with a small or large spleen (P ¼ 0.02) and RRD was 22 vs 29% (P ¼ 0.6); 15 of 22 and 8 of 24 patients survived (P ¼ 0.01). Transplant risk score A score of 1 was assigned to each of the unfavorable predictors, namely, transfusions 420; spleen size 422 cm; alternative donor. Patients with a score of 0-1 (n ¼ 24) were classified as low-risk patients and those with a score of 2-3 (n ¼ 22) were classified as high-risk patients; Table 3 outlines the transplant outcome in the two groups of patients. The speed of neutrophil engraftment and the rate of acute and chronic GVHD were similar in the high-/lowrisk patients. There were more failures for all causes of death in the high-risk patients. As a result, there was more TRM in the high-risk group (8 vs 41%, P ¼ 0.009). The RRD was also significantly increased in the high-risk group (12 vs 41%, P ¼ 0.02) ( Table 3) . As a consequence of lower TRM and lower RRD, the actuarial 5-year survival of low-risk and high-risk patients is, respectively, 77 and 8%(Po0.0001) (Table 3, Figure 2 ).
Role of splenectomy and PB CD34 þ cells in the transplant outcome. Splenectomy per se was not predictive of survival in univariate analysis and was not entered in the multivariate model. However, we wanted to test whether splenectomy had any impact on patients with a large spleen (422 cm). In total, 28 of 46 patients were splenectomized pre-transplant: the surgery was well tolerated in all patients; five patients improved their PB counts and required no transfusions after splenectomy; six patients had deep-vein thrombosis after splenectomy, mainly involving the portal system; all these six cases were clinically 
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A Bacigalupo et al asymptomatic, and deep-vein thrombosis was assessed by routine ecography; and five patients had febrile left pleural effusion, which was treated appropriately. No patient died as a consequence of splenectomy in this series and also in all of our myelofibrosis experience. The crude survival for splenectomized patients was 46% and was 55% for nonsplenectomized patients (P ¼ 0.5). Splenectomy seemed to reduce RRD in patients with a large spleen (422 cm) (RRD was 13 vs 56% in splenectomized vs non-splenectomized patients; P ¼ 0.02), but had no significant influence on RRD in patients with a small spleen (30 vs 11%;
. TRM was 40 (splenectomy) vs 33% (nonsplenectomy) in patients with a large spleen (P ¼ 0.7) and 7 vs 11% (P ¼ 0.7) in patients with a small spleen. Actuarial survival was 36 vs 11% (P ¼ 0.3) for splenectomized vs non-splenectomized patients with a large spleen and was 61 vs 77% for patients with a small spleen (P ¼ 0.5).
We had pre-transplant CD34 counts on 35 patients, and we could not enter this variable in the predictive model. The median CD34 þ cell count was 126 Â 10 6 /l. The OS for 18 patients with counts o126 Â 10 6 /l was 61% compared with 35% for 17 patients with higher counts (P ¼ 0.1). More patients with CD34 þ cell counts 4126 Â 10 6 /l were in the high-risk group (66 vs 29%, P ¼ 0.02), suggesting that CD34 þ cell counts correlate with disease burden indicated by transfusions and spleen size.
Intensity of the conditioning regimen. Patients receiving an additional dose of melphalan (30-60 mg/m 2 ) had a lower RRD (36 vs 14%, P ¼ 0.09) but a higher TRM (12 vs 38%, P ¼ 0.03). The crude survival was 48 vs 52% (P ¼ 0.7).
Status of surviving patients. Of the 23 patients who are currently alive, 19 (83%) have full donor chimerism on marrow cells and on CD3 þ PB cells (100%); the remaining four patients have an average of 32% donor chimerism on marrow cells (10-57%) and an average of 69% donor chimerism on CD3 þ cells (range, 5-100%). The 19 patients with full donor chimerism are in hematological remission, two after a second allogeneic transplant. JAK2 is wild type in 11 of 11 informative patients who had mutated JAK2 pre-transplant. The chance of becoming a long-term survivor without evidence of disease was 17 of 24 in low-risk and 2 of 22 in high-risk patients (71 vs 9%, P ¼ 0.00002).
Discussion
We have shown in this study that survival after an allogeneic transplant for patients with PMF, can be predicted using two pre-transplant parameters, spleen size and transfusion burden, together with donor type. The risk score was based on multivariate analysis and was constructed on variables, which independently predicted survival in this group of PMF patients. We assigned a score of 1 for patients with a history of more than 20 transfusions, a score of 1 for patients with a spleen larger than 22 cm and a score of 1 for patients with an alternative donor-24 patients had a score of 0-1 and 22 had a score of 2-3. We classified the first group as low risk and the second group as high risk. This transplant risk score predicted OS in univariate and multivariate analysis, after correcting for patient and transplant characteristics, including Dupriez score. This suggests that in the allogeneic transplant setting, at least with RIC regimens, spleen size and transfusion requirement are good surrogates of disease phase and they predict the outcome better than the Dupriez score, which was constructed in a non-transplant setting.
There are two possible causes of failure after an allogeneic HSCT, TRM and RRD. Patients with low-risk transplant score had both reduced TRM (8 vs 41%) and Allogeneic transplant for myelofibrosis A Bacigalupo et al reduced RRD (12 vs 41%) . Interestingly, the advantage in patients with a small spleen was mostly seen in TRM, whereas in patients with a low transfusion burden, it was seen in RRD. The number of patients is relatively small and the impression we had was that the combined use of spleen size and transfusion history was a good surrogate of disease phase; as also shown in all other hematological malignancies, disease burden at the time of transplant is a crucial variable. Therefore, a prospective trial using the transplant score to stratify patients would identify high-risk patients who may require dose escalation over our current reducedintensity transplant. How this can be achieved without increasing TRM, remains one of the major transplant challenges; in addition, in the present report, the addition of a small dose of melphalan showed a trend for reduced RRD, but also increased the TRM significantly, with the final result of equal survival. Finally, is there a role for splenectomy in PMF patients undergoing an allogeneic HSCT? Splenectomy per se was not predictive of OS, but seemed to be protective of RRD in patients with a large spleen (422 cm) (RRD was 13 vs 56% in splenectomized vs non-splenectomized patients; P ¼ 0.02), and this translated into a trend for improved survival (36 vs 11%; P ¼ 0.3). Splenectomy had no significant influence on RRD in patients with a small spleen. TRM was similar in splenectomized patients vs nonsplenectomized patients. This is in keeping with the hypothesis that the spleen contains a significant tumor load in PMF patients: when the spleen is small, one would not expect a major effect of splenectomy, but there may be a role when the spleen is very large. A recent report in 10 patients suggests that a large spleen can return to a normal size in 1 year; 24 however, the number of patients in that study is small and we have seen patients who have had more complications if transplantation was performed without removing a large spleen. The issue remains debatable, but splenectomy may be an option in these patients.
How do these results compare with other series of PMF patients undergoing an allogeneic transplant? Several studies have been published [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 25 using either myeloablative or RIC regimens. The main finding is that a proportion of PMF can be controlled with an allogeneic transplant and long-term disease-free survival can be achieved. 26 The drawback is that transplants carry a significant risk of morbidity and mortality, although RIC programs have reduced complications 26 in two reports [12] [13] TRM was less than 20%. In the present report, the overall TRM was 24%; however, when the patients were stratified by the risk score, low-risk patients had a TRM of 8%, whereas highrisk patients had a TRM of 41%. As the latter group also has a high RRD, these patients may be eligible for modified protocols and a prospective trial comparing thiotepa-based vs BU-based conditioning regimen is being planned within the Italian cooperative group, GITMO.
In conclusion, we suggest that PMF patients can be stratified as low or high risk based on spleen size, transfusion history and donor type. Low-risk patients have a low mortality and a high chance of cure of the underlying disease, whereas high-risk patients may require modified transplant procedures.
